Topical Application of BMX-010 in Subjects With Atopic Dermatitis and Plaque Psoriasis

Inclusion Criteria: * Diagnosis of either atopic dermatitis or psoriasis with mild to moderate lesions involving 1% - 25% of total body surface area * Candidate for topical treatment of atopic dermatitis or psoriasis * Negative pregnancy test for females of childbearing potential Exclusion Criteria: * Systemic pharmacotherapy or phototherapy for treatment of atopic dermatitis or psoriasis * Erythrodermic, guttate or generalized pustular psoriasis * Treatment of systemic retinoids, corticosteroids or immunosuppressive agents within 4 weeks of baseline visit * Treatment with high potency topical steroids, vitamin D analogs, keratolytics, coal tar, phototherapy, calcineurin inhibitors, or antihistamines within 2 weeks of baseline visit * UV or Dead Sea therapy within 4 weeks of baseline visit * Treatment with a biologic agent (monoclonal antibody) within 30 days or 5 times its circulating half-life (whichever is longer) prior to baseline visit * Atopic dermatitis triggered by environmental allergen or irritant * Contact dermatitis or drug-induced skin reactions * Systemic or skin infection requiring antimicrobial therapy * Systemic chemotherapy or radiotherapy within 4 weeks of baseline visit * Immunocompromise of any cause * Pregnancy, lactation or inadequate contraception * Active drug or alcohol dependence * Significant acute or chronic medical, neurological or psychiatric illness that would compromise subject's safety